Cohance Lifesciences Quarterly Results for Trading Insights
In Mar 2026, Cohance Lifesciences (COHANCE) reported revenue ₹617 Cr and net profit ₹8 Cr — revenue -27.7% YoY. Also explore Cohance Lifesciences stock price data download to track price trends across different timeframes.
COHANCE Quarterly Results — Revenue, Profit & EPS Highlights
Cohance Lifesciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Cohance Lifesciences screener.
- Revenue of ₹617 Cr in Mar 2026 (+8.1% vs Sept 2025, -27.7% vs Mar 2025)
- Net Profit of ₹8 Cr in Mar 2026 (-87.9% vs Sept 2025, -93.2% vs Mar 2025)
- EBITDA of ₹80 Cr in Mar 2026 (-41.6% vs Sept 2025)
- Operating Margin of 13.0% in Mar 2026 (-9.0pp vs Sept 2025)
- Earnings Per Share of ₹0.51 in Mar 2026 (-73.7% vs Sept 2025)
Cohance Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
COHANCE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 617 | 571 | 853 | 564 | 551 | 8.1% | -27.7% |
| Net Profit (₹ Cr) | 8 | 66 | 117 | 46 | 29 | - | - |
| EBITDA (₹ Cr) | 80 | 137 | 226 | 118 | 97 | - | - |
| EPS (₹) | 0.51 | 1.94 | 3.16 | 1.28 | 0.96 | - | - |
| Operating Margin (%) | 13.0% | 22.0% | 25.0% | 19.0% | 17.0% | - | - |
COHANCE Share Price Trend — 1-Year Movement Across Quarterly Results
Cohance Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse COHANCE cash flow statement for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
COHANCE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Cohance Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
All amounts in ₹ Crores